Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Head and Neck Squamous Cell Carcinoma
Clinical trial register · United States · industry-sponsored

Head and Neck Squamous Cell Carcinoma Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9141 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 17 Oct 2026, 03:16 UTC
9141
Studies in scope
industry-sponsored, all four open statuses
4966
Recruiting now
open to new participants
2196
Lead sponsors
across recruiting studies
Top states
California 22 Florida 16 New York 11 Illinois 10 Texas 10
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Head and Neck Squamous Cell Carcinoma trials in the USA

33 of 9141 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Study of IDP-001 in Advanced or Metastatic Solid Tumors
NCT07602842Advanced Solid Tumor, Metastatic Solid Tumor, Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
InduPro, Inc.
Phase 1/2
132
California, Florida, Indiana, New York, Texas
2026-07-08
Recruiting
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
NCT07503808Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
IDEAYA Biosciences
Phase 1
150
Colorado, Florida, Michigan, New York, Tennessee, Texas, Utah, Virginia
2026-02-24
Active, closed
Boehringer Ingelheim
Phase 1
91
Kentucky, Minnesota, Ohio
2025-05-14
Recruiting
A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors
NCT06700070Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult, Triple Negative Breast Cancer
Pure Biologics S.A.
Early Phase 1
12
Louisiana
2025-03-27
Active, closed
Gilead Sciences
Phase 2
39
Missouri, Tennessee, Texas
2025-02-18
Recruiting
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
NCT06747585Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma
Alentis Therapeutics AG
Phase 1/2
170
Arizona, California, Connecticut, Illinois, Kentucky, New Jersey, Virginia
2024-12-16
Active, closed
Merus B.V.
Phase 3
699
Alabama, California, Delaware, District of Columbia, Florida, Georgia, Illinois, Kentucky
2024-09-25
Recruiting
A Study of VET3-TGI in Patients With Solid Tumors
NCT06444815Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer
KaliVir Immunotherapeutics
Phase 1
60
California, Florida, Indiana, Pennsylvania, Texas
2024-09-16
Recruiting
Tempus AI
Observational
500
California, Florida, Georgia, Illinois, Kansas, Maryland, Massachusetts, Michigan
2024-08-01
Active, closed
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
NCT06147037Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer
AstraZeneca
Phase 1
13
California, Illinois, Nebraska, Ohio, Texas, Washington
2024-07-31
Active, closed
Merus B.V.
Phase 3
621
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2024-06-25
Active, closed
Exelixis
Phase 2/3
600
California, Florida, Georgia, Illinois, Iowa, Missouri, New Hampshire, New Jersey
2024-06-07
Recruiting
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
NCT06451497Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Pancreas Adenocarcinoma, Biliary Tract Cancer
Zumutor Biologics Inc.
Phase 1
100
Massachusetts, Texas
2024-05-22
Active, closed
Fulgent Pharma LLC.
Phase 2
46
Arkansas, California, Florida, Indiana, Texas
2024-04-10
Active, closed
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
NCT06305247Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
Ipsen
Phase 1/2
36
California, Connecticut, Tennessee, Virginia
2024-04-03
Recruiting
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
NCT06150664Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma
Compass Therapeutics
Phase 1
85
Florida, Georgia, Indiana, Massachusetts, New York, Tennessee, Washington
2024-03-19
Recruiting
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
NCT05877599Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma
AstraZeneca
Phase 1
45
Arizona, California, Florida, Massachusetts, New Jersey, New York, North Carolina, Oregon
2023-07-12
Recruiting
Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors
NCT05784688Solid Tumor, Biliary Tract Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
TiumBio Co., Ltd.
Phase 1/2
140
Texas, Washington
2023-03-10
Active, closed
TILT Biotherapeutics Ltd.
Phase 1
15
New York
2023-03-08
Active, closed
Study of CHS-114 in Participants With Advanced Solid Tumors
NCT05635643Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
Coherus Oncology, Inc.
Phase 1
87
California, Georgia, Kentucky, Maryland, Michigan, Missouri, Ohio, Tennessee
2022-12-15
Active, closed
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
NCT05565417Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cutaneous Squamous Cell Carcinoma
Immunitas Therapeutics
Phase 1/2
67
Arizona, Colorado, Florida, Oklahoma, Oregon, Tennessee, Texas, Virginia
2022-11-28
Recruiting
AbbVie
Phase 1
694
California, Illinois, Indiana, Kentucky, Michigan, Minnesota, Nebraska, North Carolina
2021-11-01
Recruiting
A Study of NX-1607 in Adults With Advanced Malignancies
NCT05107674Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma
Nurix Therapeutics, Inc.
Phase 1
345
California, Colorado, Illinois, North Carolina, Oklahoma, Texas, Virginia, Washington
2021-09-29
Active, closed
MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients
NCT04651634Head and Neck Squamous Cell Carcinoma, Oral Mucositis
DrugCCRT
MitoImmune Therapeutics
Phase 2
60
Arizona, California, Kansas, New York, North Carolina, Ohio
2021-06-21
Active, closed
ALX Oncology Inc.
Phase 2
172
California, Florida, Illinois, Kentucky, Maryland, New York, Ohio, Oregon
2021-05-10
Active, closed
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
NCT04868877Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Merus B.V.
Phase 1/2
194
California, Tennessee, Utah, Virginia
2021-04-28
Active, closed
ALX Oncology Inc.
Phase 2
189
California, Florida, Georgia, Illinois, Maryland, Massachusetts, New Jersey, New York
2021-04-02
Recruiting
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
NCT04429542Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal, Colorectal Cancer, Squamous Cell Carcinoma of the Lung
Bicara Therapeutics
Phase 1
473
California, Florida, Massachusetts, New York, North Carolina, Ohio, Pennsylvania, Rhode Island
2020-06-01
Active, closed
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
NCT04291105Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer
Vyriad, Inc.
Phase 2
87
California, Connecticut, Florida, Louisiana, Minnesota, Montana, New York, Ohio
2020-04-24
Active, closed
Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients
NCT03916627Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma
Regeneron Pharmaceuticals
Phase 2
65
New York
2019-07-23
Active, closed
Study of NEO-201 in Solid Tumors Expansion Cohorts
NCT03476681Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Uterine Cancer
Precision Biologics, Inc
Phase 1/2
121
Maryland, Virginia
2019-01-18
Active, closed
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
NCT03228667Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma
ImmunityBio, Inc.
Phase 2
40
Alaska, Arkansas, California, Florida, Indiana, Iowa, Kentucky, Massachusetts
2018-12-11
Rows per page Showing 1–33 of 33
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 17 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/head-and-neck-squamous-cell-carcinoma

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,141 studies in total at the last sync on 17 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 33 of those studies listing the condition Head and Neck Squamous Cell Carcinoma.

How many Head and Neck Squamous Cell Carcinoma trials are recruiting in the US?

14 of the 33 studies on this page are recruiting new participants as of the 17 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 19 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Head and Neck Squamous Cell Carcinoma), 33 studies
PhaseStudiesRecruitingShare
Phase 112836.4%
Phase 29127.3%
Phase 1/27321.2%
Phase 3206.1%
Early Phase 1113%
Observational113%
Phase 2/3103%

Most active sponsors

Lead sponsors with the most studies (Head and Neck Squamous Cell Carcinoma)
Lead sponsorStudiesRecruiting
Merus B.V.30
AbbVie22
ALX Oncology Inc.20
AstraZeneca21
Alentis Therapeutics AG11
Bicara Therapeutics11
Boehringer Ingelheim10
Coherus Oncology, Inc.10
Compass Therapeutics11
Exelixis10

Top states

Top states (Head and Neck Squamous Cell Carcinoma), by number of studies with a site there
StateStudies
California22
Florida16
New York11
Illinois10
Texas10
Georgia8
Kentucky7
Massachusetts7
Ohio7
Tennessee7
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.